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Abstract
A major challenge for oncologists and pharmacologists is to develop less toxic drugs that will improve the survival of lung
cancer patients. Frondoside A is a triterpenoid glycoside isolated from the sea cucumber, Cucumaria frondosa and was
shown to be a highly safe compound. We investigated the impact of Frondoside A on survival, migration and invasion in
vitro, and on tumor growth, metastasis and angiogenesis in vivo alone and in combination with cisplatin. Frondoside A
caused concentration-dependent reduction in viability of LNM35, A549, NCI-H460-Luc2, MDA-MB-435, MCF-7, and HepG2
over 24 hours through a caspase 3/7-dependent cell death pathway. The IC50 concentrations (producing half-maximal
inhibition) at 24 h were between 1.7 and 2.5 mM of Frondoside A. In addition, Frondoside A induced a time- and
concentration-dependent inhibition of cell migration, invasion and angiogenesis in vitro. Frondoside A (0.01 and 1 mg/kg/
day i.p. for 25 days) significantly decreased the growth, the angiogenesis and lymph node metastasis of LNM35 tumor
xenografts in athymic mice, without obvious toxic side-effects. Frondoside A (0.1–0.5 mM) also significantly prevented basal
and bFGF induced angiogenesis in the CAM angiogenesis assay. Moreover, Frondoside A enhanced the inhibition of lung
tumor growth induced by the chemotherapeutic agent cisplatin. These findings identify Frondoside A as a promising novel
therapeutic agent for lung cancer.
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Introduction
Lung cancer is the most common form of cancer with one of the
highest mortality rates in the world. Targeted therapies for
selected subgroups of patients constitute a remarkable progress in
the treatment of lung cancer. However, despite these advances,
controversies remain, patients die, and a cure remains elusive [1].
Natural compounds are emerging as a new generation of
anticancer agents with limited toxicity in cancer patients [2,3].
They can have high value in tumors resistant to classical
chemotherapies or resistant to tyrosine kinase inhibitors such as
gefitinib
Sea cucumbers have been valued for hundreds of years in the
Chinese diet as a food delicacy, as well as a medicine for a wide
variety of diseases. In the United States and Canada, sea
cucumber tissues are dried, pulverized and encapsulated as
nutraceuticals for over-the-counter dietary health supplements,
primarily directed at inflammatory conditions in humans and
companion animals [4]. Frondoside A is a triterpenoid glycoside
isolated from the Atlantic cucumber, Cucumaria frondosa. (See [5] for
chemical structure). Recent studies demonstrate that low concen-
trations of Frondoside A inhibit the growth and induced apoptosis
of human pancreatic, leukemia and breast cancer cells via caspase
activation [6–8].
The chemotherapeutic agents currently in use for lung cancer
are still unsatisfactory due to associated co-lateral toxicity and
drug-induced resistance [9–11] which motivate our investigation
of the impact of Frondoside A on human non-small cell lung
cancer survival, migration and invasion in vitro, and on tumor
growth, metastasis and angiogenesis in vivo alone and in
combination with cisplatin.
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Materials and Methods
Cell culture and reagents
Human lung cancer cells LNM35 (NSCLC) [12], A549 and
NCI-H460-Luc2 (Caliper LifeSciences, US) were maintained in
RPMI 1640 (Invitrogen, Paisley, UK), human melanoma MDA-
MB-435, human mammary adenocarcinoma cells MCF-7, and
human hepatoma cells HepG2 were maintained in DMEM
(Invitrogen, Paisley, UK). All media were supplemented with
antibiotics (penicillin 50 U/ml; streptomycin 50 mg/ml) (Invitro-
gen, Cergy Pontoise, France) and with 10% fetal bovine serum
(FBS, Biowest, Nouaille, France). EndoGROTM Human Umbil-
ical Vein Endothelial Cells (HUVECs) (Millipore, Temecula, CA)
were maintained in EndoGROTM-MV-VEGF Complete Media
Kit (Millipore, Temecula, CA). Cisplatin was purchased from
Sigma-Aldrich (Sigma-Aldrich, Saint-Quentin Fallavier, France).
Frondoside A was purified from Cucumaria frondosa, harvested near
Stonington, Maine and the purity (99.9%) confirmed by NMR as
previously described [13,14].
Cellular viability
Cells were seeded at a density of 5,000 cells/well into 96-well
plates. After 24 h, cells were treated for another 24 h with
different concentrations of Frondoside A (0.01–5 mM), in tripli-
cate. Control cultures were treated with 0.1% DMSO. The effect
of Frondoside A on cell viability was determined using a CellTiter-
Glo Luminescent Cell Viability assay (Promega Corporation,
Madison, USA), based on quantification of ATP, which signals the
presence of metabolically active cells. The luminescent signal was
measured using the GLOMAX Luminometer system. Data were
presented as proportional viability (%) by comparing the treated
group with the untreated cells, the viability of which is assumed to
be 100%.
Caspase 3/7 activity
LNM35 cells were seeded at the density of 5,000 cells/well into
96-well plate and treated with Frondoside A (1–2.5 mM) for 2 and
24 h, in triplicate. Caspase-3/7 activity was measured using a
luminescent Caspase-Glo 3/7 assay kit following the manufactur-
er’s instructions (Promega Corporation, Madison, USA). Caspase
reagent was added and the plate was mixed using an orbital shaker
and incubated for 2.5 h at room temperature. Luminescence was
measured using a GLOMAX Luminometer system.
Wound healing motility assay
LNM35 cells were grown in six-well tissue culture dishes until
confluence. Cultures were incubated for 10 min with Moscona
buffer. A scrape was made through the confluent monolayer with a
plastic pipette tip of 1 mm diameter. Afterwards, the dishes were
washed twice and incubated at 37uC in fresh RPMI containing
10% fetal bovine serum in the presence or absence of the non-
toxic concentrations of Frondoside A (0.1–0.5 mM). At the bottom
side of each dish, two arbitrary places were marked where the
width of the wound was measured with an inverted microscope
(objective64) (Olympus 1X71, Japan). Motility was expressed as
the average 6 S.E.M of the difference between the measurements
at time zero and the 6, 24 and 30 h time period considered.
Matrigel invasion assay
The invasiveness of the lung cancer cells LNM35 treated with
Frondoside A (0.1–1 mM) was tested using BD Matrigel Invasion
Chamber (8-mm pore size; BD Biosciences, Le Pont de Claix,
France) according to manufacturer’s protocol. The PI3 kinase
inhibitor LY294002 (20 mM) was used as a positive inhibitor of
cellular invasion. Briefly, Cells (16105 cells in 0.5 mL of media
and the indicated concentration of Frondoside A) were seeded into
the upper chambers of the system, the bottom wells in the system
were filled with RPMI supplemented with 10% fetal bovine serum
as a chemo-attractant and then incubated at 37uC for 24 h. Non-
penetrating cells were removed from the upper surface of the filter
with a cotton swab. Cells that have migrated through the Matrigel
were fixed with 4% formaldehyde, stained with DAPI and counted
in 25 random fields under a microscope. The assay was carried out
in duplicate and repeated three times for quantitative analysis.
Chorioallantoic membrane (CAM) angiogenesis assay
This assay was performed as described previously [15], with
some modifications. Briefly, fertilized eggs were incubated for 3
days at 37, 8uC with a humidity of 48%. On day 4, albumen was
removed to detach the shell from the developing CAM and a
window was made in the eggshell, exposing the CAM, and covered
with a breathing film (suprasorb FH). The eggs were returned to
the incubator until day 10, prior to application of the test
compounds. Test compound and control compound (DMEM
without 10% FBS) dissolved in DMEM without 10% FBS were
poured onto separate sterile discs (12 mm diameter), which were
allowed to dry under sterile conditions. A solution of cortisone
acetate (125 mg/disc) was poured onto all discs to prevent an
inflammatory response. Test discs probed with recombinant
human bFGF (Peprotech) served as a control for angiogenesis
stimulation. On each CAM, the disc containing control compound
and the disc containing test compound were placed at a distance of
1 cm. The windows were covered and the eggs were incubated
until day 14, before assessment of angiogenesis. Therefore, the
eggs were flooded with 10% buffered formalin and the eggs were
kept at room temperature for at least 20 minutes. The CAM, the
area of the discs included, was placed in a petri dish with 10%
buffered formalin. The plastic discs were removed and phase-
contrast pictures of the area of the plastic discs were taken. The
vascular index was measured as described previously [16].
Vascular intersections on a grid containing three concentric circles
(6, 8 and 10 mm diameter with as center the center of the disc)
were counted. The angiogenic index = (t-c)/c, with t the number of
intersections in the area covered by the test disc and c the number
of intersections in the area covered by the control disc in the same
egg. The Mann-Whitney U-test was used for statistical analysis
(p,0.05).
Vascular tube formation assay
Assessment of in vitro capillary formation used Matrigel (Becton
Dickinson, Le Pont de Claix, France). Matrigel is a squamous cell
carcinoma basement membrane matrix composed primarily of
collagen IV, laminin, entactin, and heparan sulfate proteoglycans.
The Matrigel matrix was thawed, gently mixed to homogeneity
using cooled pipettes, and diluted v/v with the EndoGROTM-MV-
VEGF Complete Media Kit medium (Millipore, Temecula, CA,
USA). Matrigel, 50 ml/well, supplemented with angiogenic pep-
tides and other effectors was used to coat the wells of 96-well
plates. The plate was then incubated for one hour at 37uC to allow
the matrix solution to solidify prior to treatment. HUVECs (at a
density of about 46104 cells/well and the indicated concentration
of Frondoside A) were plated to each well and incubated for 8 h at
37uC in 0.1 mL of EndoGROTM-MV-VEGF Complete Media
Kit medium (Millipore, Temecula, CA, USA). Then cells were
photographed using an inverted phase contrast photomicroscope.
The tubular network growth area was compared in control and
inhibitor-treated Matrigel matrix. Tube formation was quantified
by counting the number of tube-like structures formed in each
Frondoside A a Novel Lung Anticancer Agent
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well. The effect of Frondoside A on viability of the HUVEC was
determined using a CellTiter-Glo Luminescent Cell Viability assay
(Promega Corporation, Madison, USA), as previously described
for the cancer cells.
Tumor growth and metastasis assay
The animal experiments were performed in accordance with
the protocol approved by the animal ethics committee and the
Institutional Animal Care at the Faculty of Medicine & Health
Sciences/UAE University. Six-week-old athymic NMRI female
nude mice (nu/nu, Charles River, Germany) were housed in
filtered-air laminar flow cabinets and handled under aseptic
conditions. Procedures involving animals and their care were
conducted in conformity with Institutional guidelines that are in
compliance with Faculty of Medicine & Health Sciences, national
and international laws and policies (EEC Council Directive 86/
609, OJ L 358, 1, December 12, 1987; and NIH Guide for Care
and Use of Laboratory Animals, NIH Publication No. 85-23,
1985). LNM35 cells (16106 cells in 200 ml PBS) were injected
subcutaneously into the lateral flank of the nude mice. One week
Figure 1. Inhibition of cellular viability by Frondoside A. Exponentially growing LNM35 (A), A549 (B), NCI-H460-Luc2 (C), MDA-MB-435 (D),
MCF-7 (E), and HepG2 (F) cells were treated with vehicle (0.1% DMSO) and the indicated concentrations of Frondoside A. Viable cells were assayed as
described in Materials and Methods. All experiments were repeated at least three times. Columns, mean; bars, S.E.M. **Significantly different at
P,0.01, ***Significantly different at P,0.001.
doi:10.1371/journal.pone.0053087.g001
Figure 2. Induction of caspase-3/7 activity was analyzed in LNM35
cells treated for 24 h with Frondoside A (1–2.5 mM), normalized to the
number of viable cells per well and expressed as fold induction
compared with the control group. *Significantly different at P,0.05.
doi:10.1371/journal.pone.0053087.g002
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after inoculation, when tumors had reached the volume of
approximately 150 mm3, animals (six in each group) were treated
in the first protocol for 25 days with Frondoside A (0.01 and
1 mg/kg/day, ip) or carrier solution (control) in order to
determine the effect of Frondoside A alone on tumor growth
and metastasis. In the second protocol, animals were treated for
only 10 days with the lowest dose of Frondoside A (0.01 mg/kg/
day, ip), cisplatin (1 mg/kg/day, ip), or with combined Frondoside
A and cisplatin treatment. Control animals were treated with
carrier solution. Tumor dimensions and animal weights were
Figure 3. Frondoside A induces regression of established LNM35 xenografts. A) & B) Tumor volume of LNM35 xenografts inoculated
subcutaneously in nude mice and treated with Frondoside A (0.01 and 1 mg/kg, intra-peritoneal injections, respectively) or control carrier solution
alone, for a total of 25 days. Data points represent the mean6 S.E.M. of 6 mice per group. C) & D) Tumor weight obtained from the same control and
treated nude mice. Data points represent the mean6 S.E.M. of 6 mice per group. Columns, mean; bars, S.E.M. E) & F) Body weight of these mice. Data
points represent the mean 6 S.E.M. of 6 mice per group. *Significantly different at P,0.05.
doi:10.1371/journal.pone.0053087.g003
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Figure 4. The anti-angiogenic activity of Frondoside A in the xenograft tumor: Immuno-histochemical staining of lung xenograft tumors
for CD31 (microvessel density).
doi:10.1371/journal.pone.0053087.g004
Figure 5. The anti-angiogenic activity of Frondoside A in the Chorioallantoic membrane (CAM) assay in vivo: CAM was treated with
control (serum-free medium), 100 nM Frondoside A, 500 nM Frondoside A, 2 mg/mL bFGF, 2 mg/mL bFGF+500 nM Frondoside A and the
vascularization of test discs was photographed.
doi:10.1371/journal.pone.0053087.g005
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measured every 3 days. Tumor volume (V) was calculated using
the formula: V= 0.46a6b2, with ‘‘a’’ being the length and ‘‘b’’ the
width of the tumor. After sacrifice, the tumors and axillary lymph
nodes were excised and weighed.
Immuno-histochemical determination of CD31/platelet-
endothelial cell adhesion molecule 1 (PECAM-1) for
Microvessel Density
The effect of Frondoside A on angiogenesis was evaluated using
CD31 immuno-staining. The tumor tissues were quickly frozen in
isopentane at 2130uC and stored at 270uC until further
processing. Eight-mm frozen sections were fixed in acetone, and
incubated overnight with a CD31 antibody (clone MEC13.3,
1:100) (BD Pharmingen, San Jose, CA, USA). Slides were then
washed three times in PBS and incubated with secondary antibody
labeled with rhodamine (goat anti-rat 1:100) for one hour at room
temperature. The area occupied by CD31-positive microvessels
and total tissue area per section were compared between treated
and control mice. All analyses were performed in a blind fashion.
Results were expressed as means 6 S.E.M. of the number of
experiments. The difference between experimental and control
values were assessed by ANOVA followed by Dunnett’s post-hoc
multiple comparison test. Tumor growth and metastasis studies
were analyzed using the unpaired Student’s t-test. P,0.05 indicate
a significant difference.
Results
Effect of Frondoside A on cellular viability
As shown in fig. 1, Frondoside A concentrations (0.01–5 mM)
caused a concentration-dependent decrease in cell viability of
LNM35, A549, NCI-H460-Luc2, MDA-MB-435, MCF-7, and
HepG2 cells over 24 hours. The IC50 concentrations (producing
half-maximal inhibition) at 24 h were in the range of 1.7 and
2.5 mM Frondoside A for all cell lines.
Frondoside A induces caspase-3/7 activation
Caspase-3/7 activity is essential in apoptotic cell death
pathways. The relative activity of caspases 3/7 was analyzed in
LNM35 cells treated for 2 and 24 h with Frondoside A (1–
2.5 mM), and normalized to the number of cells per well. As shown
in Fig. 2, caspase 3/7 activity increased by 2.5- and 10.8-fold in
LNM35 cells treated for 24 h with Frondoside A 1 and 2.5 mM
respectively. Similar effect was observed after treatment with
Frondoside A (1–2.5 mM) for 2 h (data not shown).
Impact of Frondoside A on LNM35 xenografts
To confirm the pharmacological relevance of our in vitro data,
the anticancer activity of Frondoside A was investigated in vivo in
athymic mice inoculated with LNM35 lung cancer cells. The
growth of the LNM35 human tumor xenografts was monitored
every third or fourth day for 25 consecutive days after daily i.p.
injection of 0.01 mg and 1 mg/kg of Frondoside A. Treatment
with the lowest dose of Frondoside A (0.01 mg/kg/day) reduced
the volume of the LNM35 xenografts by 41% (Fig. 3A). A similar
difference was also found in tumor weight at the end of the
experiment (2.1+/20.3 g versus 4.5+/20.8 g; P,0.05; Fig. 3C).
Treatment with the highest dose (100 times more) of Frondoside A
(1 mg/kg/day) reduces about 43.9% tumor volume of the LNM35
xenografts (Fig. 3B). Almost similar difference was found in tumor
weight at the end of the experiment (3+/20.5 g versus 4.5+/
20.8 g; Fig. 3D). This experiment clearly demonstrated that the
lowest dose of Frondoside A (0.01 mg/kg/day) is optimal for the
inhibition of tumor growth. There were no manifest undesirable
effects of Frondoside A treatment on animal behaviour or body
weight in either experiment (Fig. 3E and 3F). In addition, there
were no visible abnormalities at necropsy, or any other obvious
signs of toxicity as previously described by our team [7].
Inhibition of angiogenesis by Frondoside A in the
xenografted tumors and the CAM assay in vivo and in the
capillary-like structures in vitro
Angiogenesis is an attractive target in cancer therapy not only
because it supplies oxygen and nutrients for the survival of tumor
cells but also provides the route for metastatic spread of these
cancer cells. First, we demonstrate that in the proliferating areas at
the periphery of the tumor, microvessel density (measured by
CD31 staining) was significantly reduced by Frondoside A
(0.01 mg/kg/day) (Fig. 4, right panel) in comparison with the
control-treated tumors (Fig. 4, left panel). Next, we used the
CAM assay involving the coordination and integration of
multicellular responses during development of the chick embryo
to confirm this potential anti-angiogenic effect of Frondoside A. As
shown in Fig. 5 and 6, bFGF (2 mg/ml), stimulated 15% new
vessel formation with angiogenic indices statistically different
compared with the control DMEM medium. Frondoside A (100
and 500 nM) inhibited basal angiogenesis in a concentration-
dependent manner with respectively 7% and 12% inhibition of
angiogenic index compared to control (Fig. 5 and 6). The
formation of new blood vessels induced by bFGF was also
completely suppressed by Frondoside A (500 nM) (Fig. 5 and 6).
Finally, to assess whether the anti-angiogenic effect of Frondoside
A involves a direct interaction of the compound with endothelial
cells, we conducted comparative studies on the formation of
capillary-like structures in vitro, using HUVECs plated on Matrigel-
coated plates. As shown in Fig. 7A, human endothelial cells have
the ability to form capillary structures when seeded and cultured
on top of Matrigel substrate. Control cells move from their initial
uniform pattern of dispersed cell layers and associate to form a
network of cell clusters connected by long, multicellular processes
leading to the formation of tube-like structures. Addition of non-
toxic concentrations of Frondoside A (0.01–1 mM) resulted in a
marked inhibition of this spontaneous angiogenic phenotype
(Fig. 7A, and 7B). Frondoside A induced inhibition of this
spontaneous angiogenic phenotype occurred without significant
reduction of cell viability (Fig. 7C). Taken together, these data
confirm a strong anti-angiogenic potential of Frondoside A.
Figure 6. Quantification of CAM angiogenesis assay: Bars
indicate angiogenic indices (%) of CAM’s probed with 2 mg/mL bFGF,
100 nM Frondoside A, 500 nM Frondoside A, 2 mg/mL bFGF+500 nM
Frondoside A. Data represents mean 6 SD (Mann-Whitney U-test, *:
p,0.05, ***: p,0.01). In each experiment, six eggs were tested per
condition.
doi:10.1371/journal.pone.0053087.g006
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Frondoside A also impairs lung cancer cell migration and
invasion in vitro and metastasis in vivo
Cancer progression is associated with the abrogation of normal
controls that limit cell migration and invasion, eventually leading
to metastasis. Lung cancer patients are at high risk of recurrence in
the form of metastatic disease. Metastasis starts with cell migration
in the primary tumor, leading to local tissue invasion and entry
into lymph or blood vessels. The ability of Frondoside A to reduce
cellular migration was investigated using a classic in vitro wound
healing model. Frondoside A reduced cellular migration of
LNM35 cells in a concentration- and time-dependent manner
(Fig. 8A). Similarly, Frondoside A impaired the invasion of
LNM35 cells in matrigel invasion assay (Fig. 8B). Frondoside A
induced inhibition of cellular migration and matrigel invasion
occurred without significant reduction of cell viability (Fig. 1A).
Next, we assessed the metastatic behavior of the human
pulmonary cell line LNM35 by examining axillary lymph nodes.
Histological examination of the lymph nodes in LNM35-bearing
mice revealed the presence of LNM35 cells in all lymph nodes
from both the control and Frondoside A treated mice (data not
shown). In the control-treated group, the mean lymph nodes
weight was 548.5+/2112.8 mg compared with 256+/243.3 and
268.8+/255.7 mg in the groups treated with Frondoside A
0.01 mg and 1 mg/kg/day, respectively (Fig. 8C and 8D).
Figure 7. Impact of Frondoside A on the formation of capillary-like structures by HUVECs in vitro. A) Patterns of angiogenesis induced
by human umbilical vein endothelial cells (HUVEC) cultured on Matrigel matrix in 96-well plates in the absence or presence of the Frondoside A. B)
Quantification of tubular morphogenesis induced in HUVEC cells cultured in the absence or presence of Frondoside A. Tube formation was
determined by the length of tube-like structures containing connected cells. Data are mean 6 S.E.M. from three separate experiments. Asterisks
indicate that significantly different values were obtained in the presence of the indicated inhibitors vs. the corresponding control stimulation.
***Significantly different at P,0.001. C) HUVEC cells were treated with vehicle (0.1% DMSO) and the indicated concentrations of Frondoside A. Viable
cells were assayed as described in Materials and Methods. All experiments were repeated at least three times. Columns, mean; bars, S.E.M.
doi:10.1371/journal.pone.0053087.g007
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Frondoside A enhances the anticancer activity of
cisplatin
As shown in Fig. 9A, daily administration of Frondoside A to
nude mice reduced the growth of LNM35 human tumor
xenografts by 40.3% at day 10. Inhibition of LNM35 tumor
xenograft growth by Frondoside A was comparable with that
produced by the DNA-damaging anticancer agent cisplatin
(46.9%). Combined treatment of Frondoside A with cisplatin
resulted in a remarkable potentiation (67.6%; P,0.05) of the
cisplatin therapeutic effect (Fig. 9A). There were no manifest side
effects of the combined treatment on animal behaviour or body
weight (Fig. 9B).
Discussion
Despite advances in molecular biology of lung cancer, improved
diagnosis, and even optimal target therapies, the current protocols
for the treatment of lung cancer are still insufficient to produce
striking clinical benefits and the cure of lung cancer patients
remains unsuccessful. The current targeted therapy drugs develop
resistance and they are very expensive and not available to the
majority of lung cancer patients in the world. Many drugs have
relatively low activity; few patients are cured, with a brief, if any,
increase in survival [17]. The history of anti-cancer agents, such as
paclitaxel, shows that the mechanism of action was identified
several years after its clinical efficacy was demonstrated. Despite
not knowing the drug’s mechanism of action, we believe that the in
vitro as well as the strong in vivo anti-cancer effects of Frondoside A
should translate in the clinic to a new potent anti- lung cancer
agent.
In the present study, we investigated the impact of Frondoside A
on lung cancer cells progression. We showed that Frondoside A
caused concentration-responsive (0.01–5 mM) decreases in viability
of LNM35, A549, and NCI-H460-Luc2 cells over 24 hours
through the caspase 3/7-dependent cell death pathway. The IC50
concentrations (producing half-maximal inhibition) at 24 h were
between 1.7 and 2.5 mM Frondoside A. These results are
consistent with previously published results that low concentration
of Frondoside A inhibits the growth of human pancreatic cancer
cells and induced apoptosis through caspase 9/3/7, increased bax,
decreased bcl-2 and mcl-1, and arrested cell cycle and up-
regulated p21 [8], induced apoptosis in human leukemia cells via
Figure 8. Frondoside A also impairs lung cancer cell migration and invasion in vitro and metastasis in vivo. A) Wounds were introduced
in LNM35 confluent mono-layers cultured in the presence or absence (control) of Frondoside A (0.1–0.5 mM). The mean distance that cells travelled
from the edge of the scraped area for 6, 24, and 30 h at 37uC was measured in a blinded fashion, using an inverted microscope (46magnifications).
Data are means6 S.E.M. of two independent experiments. B) LNM35 cells were incubated for 24 h in the presence or absence of Frondoside A (0.01–
1 mM) and LY294002 (20 mM). Cells that invaded into Matrigel were scored as described in Materials and Methods. Columns, mean; bars, S.E.M. Lymph
nodes metastasis weight of established human lung cancer xenografts treated with Frondoside A 0.01 mg/kg (C) and 1 mg/kg (D) every day for 25
days. Columns, mean; bars, S.E.M. *Significantly different at P,0.05, **Significantly different at P,0.01, ***Significantly different at P,0.001.
doi:10.1371/journal.pone.0053087.g008
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caspase activation [6], and significantly decreases the viability of
the estrogen receptor (ER)-negative MDA-MB-231 breast cancer
cells by inducing apoptosis via the Caspase9-Caspase3/7 intrinsic
pathway [7]. It has also been demonstrated that Frondanol A5, an
impure extract of Cucumaria frondosa skin from which Frondoside A
is originally derived, induced growth inhibition at S and G2-M
phase with a decrease in Cdc25c and an increase in p21WAF1/CIP1
with significant apoptosis associated with H2AX phosphorylation
and caspase-2 cleavage in the colon cancer-derived HCT116 cells
[4]. A second paper also demonstrated that Frondanol-A5P, a
polar precipitate sub-fraction of Frondanol-A5, inhibited prolifer-
ation and induced G2/M phase cell cycle arrest in two pancreatic
cancer cells with decreased expression of cyclin A, cyclin B, and
cdc25c [18]. This anticancer effect of Frondoside A is not tissue
specific, and in this context we demonstrated that Frondoside A
induced a concentration-dependent decrease in cell viability of the
melanoma MDA-MB-435, the breast MCF-7, and the hepatoma
HepG2 cells.
To assess the effects of Frondoside A on lung tumor
development in vivo, LNM35 xenografts were made in immuno-
suppressed mice. We demonstrated that intraperitoneal adminis-
tration of Frondoside A caused a strong regression of established
tumors. Maximum inhibition was obtained with the low dose of
0.01 mg/kg/day for 25 days. A 100 times higher dose gives similar
effects indicating that increasing the dose will not improve the anti-
cancer efficacy of Frondoside A. The cancer inhibitory effect of
Frondoside A has been observed previously on AsPC-1 pancreatic
and MDA-MB-231 xenografts in athymic mice [7,8]. This anti-
tumor effect of Frondoside A may be partly due to its immuno-
stimulatory effect [13] and/or anti-angiogenic effect. In this study,
we demonstrated for the first time, that Frondoside A is a strong
anti-angiogenic agent. It reduces the microvessel density (mea-
sured by CD31 staining) in the xenografted tumor treated with
Frondoside A and also significantly reverse basal and bFGF
induced angiogenesis in the CAM angiogenesis assay. Similarly,
Frondoside A completely suppressed capillary structure formation
on Matrigel substratum by human endothelial cells.
Angiogenesis is an attractive target in cancer therapy not only
because it supplies oxygen and nutrients for the survival of tumor
cells but also provides the route for metastatic spread of these
cancer cells. Cancer progression is associated with abrogation of
the normal controls that limit cell migration and invasion, leading
eventually to metastasis. As metastasis is the major cause of death
in cancer patients, the development of new treatment regimens
that reduce invasion and metastasis is highly important in cancer
therapy. In this context, we demonstrated that Frondoside A
induced a highly significant time- and concentration-dependent
inhibition of cell migration, invasion in vitro and metastasis in vivo.
These results are in agreement with our previous study showing
that Frondoside A at concentrations that are not cytotoxic to the
cells exerts a strong inhibitory effect on both the migratory and
invasive properties of MDA-MB-231 breast cancer cells [7] and
with another recent study demonstrating that Frondoside A
inhibits breast cancer metastasis to the lungs [19].
Building on aforementioned results, and knowing from clinical
trials that single agent treatments rarely result in clinical benefits to
cancer patients, and that combination therapy are necessary for
effective treatment of tumors, we investigated the therapeutic
advantage of combination of cisplatin, (a first line treatment of
lung cancer), with Frondoside A in nude mice bearing LNM35
xenografts. We found that Frondoside A enhances the inhibition of
lung tumor growth induced by the chemotherapeutic agent
cisplatin. These findings identify Frondoside A as a promising
novel therapeutic agent for lung cancer and perhaps other cancers
too.
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Figure 9. Antitumor activity of Frondoside A alone or in
combination with the anticancer drug, cisplatin, against
human lung tumor xenografts in athymic nude mice. A)
Frondoside A enhances cisplatin efficacy against NSCLC LNM35 cells
growing as xenografts. B) Impact of Frondoside A and cisplatin alone or
in combination on body weight. *Significantly different at P,0.05.
doi:10.1371/journal.pone.0053087.g009
Frondoside A a Novel Lung Anticancer Agent
PLOS ONE | www.plosone.org 9 January 2013 | Volume 8 | Issue 1 | e53087
References
1. Mann J (2002) Natural products in cancer chemotherapy: past, present and
future. Nat Rev Cancer 2: 143–148.
2. Molinski TF, Dalisay DS, Lievens SL, Saludes JP (2009) Drug development from
marine natural products. Nat Rev Drug Discov 8: 69–85.
3. Kuno T, Tsukamoto T, Hara A, Tanaka T (2012) Cancer chemoprevention
through the induction of apoptosis by natural compounds. Journal of Biophysical
Chemistry 3: 156–173.
4. Janakiram NB, Mohammed A, Zhang Y, Choi CI, Woodward C, et al. (2010)
Chemopreventive effects of Frondanol A5, a Cucumaria frondosa extract,
against rat colon carcinogenesis and inhibition of human colon cancer cell
growth. Cancer Prev Res (Phila) 3: 82–91.
5. Girard M, Be´langer J, ApSimon JW, Garneau FX, Harvey C, et al. (1990)
Frondoside A. A novel triterpene glycoside from the holothurians Cucumaria
frondosa. Can J Chem 68: 11–18.
6. Jin JO, Shastina VV, Shin SW, Xu Q, Park JI, et al. (2009) Differential effects of
triterpene glycosides, frondoside A and cucumarioside A2-2 isolated from sea
cucumbers on caspase activation and apoptosis of human leukemia cells. FEBS
Lett 583: 697–702.
7. Al Marzouqi N, Iratni R, Nemmar A, Arafat K, Ahmed Al Sultan M, et al.
(2011) Frondoside A inhibits human breast cancer cell survival, migration,
invasion and the growth of breast tumor xenografts. Eur J Pharmacol 668: 25–
34.
8. Li X, Roginsky AB, Ding XZ, Woodward C, Collin P, et al. (2008) Review of the
apoptosis pathways in pancreatic cancer and the anti-apoptotic effects of the
novel sea cucumber compound, Frondoside A. Ann N Y Acad Sci 1138: 181–
198.
9. Dempke WC, Suto T, Reck M (2010) Targeted therapies for non-small cell lung
cancer. Lung Cancer 67: 257–274.
10. Spira A, Ettinger DS (2004) Multidisciplinary management of lung cancer.
N Engl J Med 350: 379–392.
11. Korpanty G, Smyth E, Carney DN (2011) Update on anti-angiogenic therapy in
non-small cell lung cancer: Are we making progress? J Thorac Dis 3: 19–29.
12. Kozaki K, Miyaishi O, Tsukamoto T, Tatematsu Y, Hida T, et al. (2000)
Establishment and characterization of a human lung cancer cell line NCI-H460-
LNM35 with consistent lymphogenous metastasis via both subcutaneous and
orthotopic propagation. Cancer Res 60: 2535–2540.
13. Aminin DL, Agafonova IG, Kalinin VI, Silchenko AS, Avilov SA, et al. (2008)
Immunomodulatory properties of frondoside A, a major triterpene glycoside
from the North Atlantic commercially harvested sea cucumber Cucumaria
frondosa. J Med Food 11: 443–453.
14. Aminin DL, Koy C, Dmitrenok PS, Mu¨ller-Hilke B, Koczan D, et al. (2009)
Immunomodulatory effects of holothurian triterpene glycosides on mammalian
splenocytes determined by mass spectrometric proteome analysis. J Proteomics
72: 886–906.
15. Derycke L, Morbidelli L, Ziche M, De Wever O, Bracke M, et al. (2006) Soluble
N-cadherin fragment promotes angiogenesis. Clin Exp Metastasis 23: 187–201.
16. Harris-Hooker SA, Gajdusek CM, Wight TN, Schwartz SM (1983) Neovascular
responses induced by cultured aortic endothelial cells. J Cell Physiol 114: 302–
310.
17. Hait WN (2010) Anticancer drug development: the grand challenges. Nat Rev
Drug Discov 9: 253–254.
18. Roginsky AB, Ding XZ, Woodward C, Ujiki MB, Singh B, et al. (2010) Anti-
pancreatic cancer effects of a polar extract from the edible sea cucumber,
Cucumaria frondosa. Pancreas 39: 646–652.
19. Ma X, Kundu N, Collin PD, Goloubeva O, Fulton AM (2011) Frondoside A
inhibits breast cancer metastasis and antagonizes prostaglandin E receptors EP4
and EP2. Breast Cancer Res Treat.
Frondoside A a Novel Lung Anticancer Agent
PLOS ONE | www.plosone.org 10 January 2013 | Volume 8 | Issue 1 | e53087
